Doherty Institute
The Doherty Institute is a joint venture between The University of Melbourne and The Royal Melbourne Hospital, conducting infectious disease research, public health interventions, and graduate education with 1,100+ researchers across 120+ groups serving global healthcare systems and public health agencies.
- Company typePrivate
- Founded2014
- HeadquartersMelbourne, Australia
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
Doherty Institute firmographics
Firmographics- Name
- Doherty Institute
- Legal name
- Peter Doherty Institute for Infection and Immunity
- Website
- https://doherty.edu.au
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- The Doherty Institute is a joint venture between The University of Melbourne and The Royal Melbourne Hospital, conducting infectious disease research, public health interventions, and graduate education with 1,100+ researchers across 120+ groups serving global healthcare systems and public health agencies.
- Ownership category
- akta.pro rank
Doherty Institute industry classification
Industry- Product category
- Infectious Disease Research
- NAICS
- Medical and Diagnostic Laboratories (62151), Scientific Research and Development Services (5417), Medical Laboratories (621511)
- SIC
- Services-Hospitals (8060), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Academic Medical Centers (AMCs) & Teaching Hospitals (HLAFAAAA)
- akta.pro secondary industries
- General Infectious Disease (HLAKAGAA), Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA)
Keywords
Where Doherty Institute is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Offices1 record
Markets served
Doherty Institute business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Infrastructure, Operations, Others
Revenue model
- Research Grants: Competitive research grants from global health organizations such as CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) providing AUD$2.68 million for antibiotic-resistant pneumonia research.
- Philanthropic Funding: The Cumming Global Centre for Pandemic Therapeutics has secured $100 million in competitive global funding. Donations support the institute's vision to improve health globally through discovery research.
- Education and Training: Revenue from educational programs including PhD, Honours, Masters, undergraduate courses, and professional development offerings.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Doherty Institute product offering
Product offeringCore offering
The Doherty Institute is a joint venture between The University of Melbourne and The Royal Melbourne Hospital that conducts infectious disease research, delivers public health and reference laboratory services, and provides undergraduate, graduate, and postgraduate education. Its portfolio spans antimicrobial resistance, bacterial and parasitic infections, viral diseases, immunology, and computational genomics, supported by the Cumming Global Centre for Pandemic Therapeutics and advanced shared laboratory facilities (electron microscopy, flow cytometry, genomics, imaging).
Product overview
The Doherty Institute is a joint venture between the University of Melbourne and The Royal Melbourne Hospital focused on preventing, treating, and curing infectious diseases. The Institute operates as a unified research organization combining three core service areas: (1) Infectious Disease Research across themes including Antimicrobial Resistance, Bacterial and Parasitic Infections, Viral Infectious Diseases, Immunology, and Computational Science and Genomics; (2) Public Health Services addressing population-level health challenges and global health preparedness; and (3) Education and Training spanning undergraduate through PhD programs. Research Facilities including Electron Microscopy, Flow Cytometry, Genomics, and Imaging are available as shared infrastructure. The Cumming Global Centre for Pandemic Therapeutics operates as a dedicated research centre focused on platform technologies for future pandemic preparedness.
Differentiator
Problem solved
Functional benefit
Brands
- Cumming Global Centre for Pandemic Therapeutics: A mission-driven, global research centre to enable rapid design and development of therapeutics for future pandemics.
Products and services
- Infectious Disease Research Core research activities focused on preventing, treating, and curing infectious diseases including antimicrobial resistance, bacterial infections, parasitic infections, viral diseases, and immunology. Delivered to health systems, public health agencies, and academic collaborators.
- Public Health Services Public health research and interventions addressing population-level infectious disease challenges, health systems optimization, and global health preparedness.
- Education and Training Programs Undergraduate, graduate, PhD, Honours & Masters programs, clinical graduate research training, and professional development opportunities in infectious disease and immunology.
- Shared Research Facilities Shared research facilities including Electron Microscopy, Flow Cytometry, Genomics, and Imaging services available for use by researchers across the institute and its partners.
- Cumming Global Centre for Pandemic Therapeutics A mission-driven, global research centre dedicated to developing new platform technologies for rapid design and development of therapeutics for pathogens with pandemic potential.
- CRISPR-Based Point-of-Care STI Test Rapid point-of-care diagnostic combining isothermal amplification with CRISPR technology targeting two different pathogen sites to detect all major bacterial STIs (chlamydia, gonorrhea, syphilis, trichomonas, Mycoplasma genitalium) plus gonorrhea antibiotic resistance markers in under an hour, designed for clinicians and public health services in resource-limited settings.
Quantifiable outcome
- Cefazolin reduced 90-day mortality from 17% to 15% and kidney injury from 20% to 14% compared to flucloxacillin for golden staph infections
- +2 more outcomes
Companies that use Doherty Institute
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Doherty Institute technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Doherty Institute partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered flagship, core and minor.
- Cumming Global Centre for Pandemic TherapeuticsflagshipA mission-driven global research centre housed within the Doherty Institute to enable rapid design and development of therapeutics for future pandemics. The Centre has secured $100 million in competitive global funding and develops new platform technologies for pandemic preparedness.
- University of NewcastlecoreCo-led the SNAP Trial (world's largest international clinical trial for Staphylococcus aureus infections) alongside the Peter Doherty Institute. The landmark research published in New England Journal of Medicine and The Lancet.
- 150+ International HospitalscoreOver 150 hospitals across more than 14 countries participated in the SNAP Trial, the largest international clinical trial ever conducted for Staphylococcus aureus infections.
- Moderna mRNA Access ProgramminorCollaboration through the Moderna mRNA Access program for pandemic preparedness and therapeutic development research.
- Charité University HospitalcoreResearch partnership between the Doherty Institute and Charité University Hospital (Germany), with Expressions of Interest open for 2026 collaboration projects.
- The University of MelbourneflagshipJoint venture partner - The University of Melbourne provides academic oversight, research leadership, and student education programs including PhD, Honours, Masters, and undergraduate training.
- The Royal Melbourne HospitalflagshipJoint venture partner - The Royal Melbourne Hospital provides clinical integration, hospital-based research facilities, and pathways for translating research into patient care.
- Australian Institute for Infectious Disease (AIID)coreCollaborative initiative bringing together Australian expertise in infectious disease research for coordinated pandemic preparedness and response.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Doherty Institute competitors and assessment
Company assessmentBroad incumbents
- Francis Crick Institute: London-based biomedical research institute with significant infectious-disease and immunology programs alongside broader life-science work. Comparable as a large-scale research-institute operating model with translational research capabilities.
- The Scripps Research Institute: U.S. nonprofit research organization with deep immunology and infectious-disease programs. Comparable as a high-impact, grant-funded research enterprise that frequently publishes in NEJM/Cell-tier journals.
- Institut Pasteur: Paris-based global flagship for infectious-disease research with a comparable combination of reference-laboratory services, public-health mission, and graduate training. Comparable in scope and scientific brand, though materially larger in scale.
- Broad Institute: MIT/Harvard-affiliated genomics and infectious-disease institute. Comparable through its infectious-disease and genomic-surveillance programs (e.g., the Broad's viral sequencing leadership during COVID-19) and large, multi-source funding model.
- Walter and Eliza Hall Institute of Medical Research (WEHI): Australia's oldest medical research institute, located adjacent to the Royal Melbourne Hospital. Operates in adjacent infectious-disease and immunology themes but with a broader biomedical mandate, making it a strong incumbent peer for talent, grants, and clinical-translation partnerships.
- National Institute of Allergy and Infectious Diseases (NIAID): U.S. federal lead agency for infectious-disease and immunology research. Comparable through its pandemic-preparedness, AMR, and clinical-trials portfolio, though operating at dramatically larger scale.
Direct peers
- Jenner Institute: Oxford-based vaccine and infectious-disease research institute. Closely comparable in translational infectious-disease focus, clinical-trial networks, and pandemic-preparedness orientation.
- Burnet Institute: Also Melbourne-based and focused on infectious disease, immunology, and public-health research. Highly comparable in mission, geography, and operating model — Burns and Doherty routinely collaborate and compete for the same Australian grant and philanthropic dollars.
- Australian Institute for Infectious Disease (AIID): Doherty's named collaborative partner for coordinated pandemic preparedness. Directly comparable as an Australian infectious-disease research consortium with overlapping translational and public-health mandates.
- The Kirby Institute: UNSW-affiliated Australian institute dedicated to HIV, viral hepatitis, STIs, and infectious-disease epidemiology. Mirrors Doherty's infectious-disease research mandate with overlapping themes in STIs, AMR, and public-health translation.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Doherty Institute social profiles
Digital presenceDoherty Institute financial estimates
Financial estimateRevenue estimate
Valuation estimate
Doherty Institute leadership team
Management profileNumber of profiles
Profiles1 record
Doherty Institute subsidiaries and ownership
Company hierarchySubsidiaries1 record
Doherty Institute funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Doherty Institute M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Doherty Institute
What does Doherty Institute do?
The Doherty Institute is a joint venture between The University of Melbourne and The Royal Melbourne Hospital that conducts infectious disease research, delivers public health and reference laboratory services, and provides undergraduate, graduate, and postgraduate education. Its portfolio spans antimicrobial resistance, bacterial and parasitic infections, viral diseases, immunology, and computational genomics, supported by the Cumming Global Centre for Pandemic Therapeutics and advanced shared laboratory facilities (electron microscopy, flow cytometry, genomics, imaging).
Is Doherty Institute a public or private company?
Doherty Institute is a private company. It is classified as state government owned and is currently operating.
When was Doherty Institute founded?
Doherty Institute was founded in 2014. It employs 501 to 1,000 people.
Where is Doherty Institute based?
Doherty Institute is headquartered in Melbourne, Australia, in the Oceania region.
How does Doherty Institute make money?
Three revenue lines are on record. Research Grants are the primary driver. The others are philanthropic Funding and education and Training.
Who are Doherty Institute's main competitors?
Broad incumbents on record are Francis Crick Institute, The Scripps Research Institute, Institut Pasteur, Broad Institute, Walter and Eliza Hall Institute of Medical Research (WEHI) and National Institute of Allergy and Infectious Diseases (NIAID). Direct peers are Jenner Institute, Burnet Institute, Australian Institute for Infectious Disease (AIID) and The Kirby Institute.
Does Doherty Institute have an API?
No public API is recorded for Doherty Institute.
What industry is Doherty Institute in?
Doherty Institute's product category is Infectious Disease Research. Its primary akta.pro industry code is HLAFAAAA, Academic Medical Centers (AMCs) & Teaching Hospitals, with a secondary code of HLAKAGAA, General Infectious Disease. Its NAICS code is 62151 and its SIC code is 8060.